ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 1339 • ACR Convergence 2023

    Neutrophil Activation and Formation of Neutrophil Extracellular Traps Are Associated with Response to Abatacept in Patients with Moderate to Severe Rheumatoid Arthritis

    Ting Wang1, Natalia V. Giltiay2, Christian Lood2 and Bobby Kwanghoon Han2, 1University of Washington, Seattle, WA, 2Division of Rheumatology, University of Washington, Seattle, WA

    Background/Purpose: Neutrophil activation and formation of neutrophil extracellular traps (NETs) have been implicated in the pathogenesis of rheumatoid arthritis (RA). Calprotectin, a neutrophil activation marker,…
  • Abstract Number: 1628 • ACR Convergence 2023

    The Impact of Cardiovascular and Cerebrovascular Disease on the Risk of Dementia in Rheumatoid Arthritis. a Mediation Analysis

    Edward Lovering1, Chanakya Kodishala2, Rakesh Kumar1, Cynthia Crowson1, Ryan Lennon1, John Davis1 and Elena Myasoedova1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic Rochester Minnesota, Rochester, MN

    Background/Purpose: Alzheimer's disease and related dementias have an immense disease burden, with predicted continuous increase in incidence and prevalence. Systemic inflammation plays a major role…
  • Abstract Number: 1721 • ACR Convergence 2023

    The Therapeutic Effects of Gingival Mesenchymal Stem Cells and Their Exosomes in a Chimeric Model of Rheumatoid Arthritis

    shane Bruckner1, Braden Zeno2, Vittoria Capria1, William Willis3, Latha Prabha Ganesan1 and wael Jarjour1, 1Ohio State University, Columbus, OH, 2Ohio State University, Upper Arlington, OH, 3Ohio State University, Reynoldsburg, OH

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease that leads to progressive joint destruction involving multiple joints. There is a large body of…
  • Abstract Number: 1740 • ACR Convergence 2023

    Exploring Disease-Associated DNA Methylome Alterations in Rheumatoid Arthritis: Potential Diagnostic and Prognostic Biomarkers

    Arkaitz Mucientes1, Martín-Núñez Gracia María2, José Lisbona-Montañez3, Patricia Ruiz-Limon4, Rocío Redondo-Rodríguez5, SARA MANRIQUE6, Inmaculada Ureña5, Laura Cano-García5, Isabel Moreno-Indias1, Natalia Mena Vazquez7 and Antonio Fernandez-Nebro8, 1IBIMA Plataforma BIONAND, Málaga, Spain, 2Universidad de Málaga, Departamento de Medicina y Dermatología, Málaga, Spain, 3Universidad de Málaga, Departamento de Medicina y Dermatología, Moclinejo, Spain, 4IBIMA Plataforma BIONAND, Cordoba, Spain, 5Division of Rheumatology, Hospital Regional Universitario Carlos Haya, Málaga, Spain, 6Division of Rheumatology, Hospital Regional Universitario Carlos Haya, Malaga, Spain, 7IBIMA, Málaga, Spain, 8Hospital Regional Universitario de Málaga, Malaga, Spain

    Background/Purpose: The etiology of rheumatoid arthritis (RA) is not fully understood. It is accepted that RA results from the interplay of genetic and environmental factors.…
  • Abstract Number: 1756 • ACR Convergence 2023

    Circulating CD4+CD25+CD127-FoxP3+CD39+ T Cells Predict the Response to Methotrexate Across Basal Disease Activity Strata in Early Rheumatoid Arthritis

    Maria-Eugenia Miranda-Carus1, Beatriz Nieto-Carvalhal1, Alejandro Villalba2, Laura Nuño1, Marta Benito-Miguel3, Marta Novella-Navarro4, Irene Monjo5, Diana Peiteado1, Sara García-Carazo1 and Alejandro Balsa4, 1Hospital Universitario La Paz - IdiPAZ, Madrid, Spain, 2Rheumatology Department, La Paz University Hospital, Madrid, Spain, 3Universidad Nebrija, Physiology, Madrid, Spain, 4Hospital Universitario La Paz, Madrid, Spain, 5University Hospital La Paz, Madrid, Spain

    Background/Purpose: A subset of human FoxP3+ regulatory T (Treg) cells expresses CD39 (Treg39+) and hydrolyses proinflammatory adenine nucleotides released at inflammatory foci, rendering the antiinflamatory…
  • Abstract Number: 1772 • ACR Convergence 2023

    Rheumatoid Arthritis-Specific Rheumatoid Factors Develop in Some COVID-19 Patients

    Adam Titi1, Ryan Adyniec2, Nat Murren1 and Miriam Shelef1, 1University of Wisconsin, Madison, WI, 2University of Wisconsin-Madison, Madison, WI

    Background/Purpose: Rheumatoid factors (RFs), antibodies canonically known to bind two conformational epitopes of IgG Fc, are a hallmark of rheumatoid arthritis (RA) but also can…
  • Abstract Number: 1887 • ACR Convergence 2023

    Total-body PET Quantitative Biomarkers Reveal Key Differences in Enthesitis Between Rheumatoid and Psoriatic Arthritis Patients

    Dario Mazza1, Siba Raychaudhuri2, Yasser Abdelhafez1 and Abhijit Chaudhari3, 1University of California Davis, Sacramento, CA, 2UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, 3UC Davis School of Medicine, Sacramento, CA

    Background/Purpose: To evaluate the ability of total-body PET (TB-PET) biomarkers to quantify enthesitis in Psoriatic (PsA) and Rheumatoid Arthritis (RA). We hypothesize that objective characterization…
  • Abstract Number: 2034 • ACR Convergence 2023

    Assessment of the Immediate and Short-term Impact of an Information Course on Patients’ Knowledge About Rheumatoid Arthritis: Evaluation Using a Self-prepared and Validated Assessment Questionnaire

    Ranjan Gupta1, Rudra Prosad Goswami2, Manshi Yadav1, Sandhya Saini1, Anju Mohan1 and Vanamail Perumal1, 1All India Institute of Medical Sciences, New Delhi, India, 2Department of Rheumatology, All India Institute of Medical Sciences, New Delhi, India

    Background/Purpose: Long-term outcomes in rheumatic diseases can be improved by improving patients' knowledge, beliefs and perception about their disease which can help them in coping…
  • Abstract Number: 2110 • ACR Convergence 2023

    Rheumatoid Arthritis and Changes in Pulmonary Function Measures on Spirometry in a Prospective Longitudinal Cohort of Smokers

    Keigo Hayashi1, Gregory McDermott1, Pierre-Antoine Juge2, Matthew Moll1, Michael Cho1, Tracy J. Doyle1, Gregory Kinney3, Danielle Sansone-Poe3, Kendra Young3, Paul Dellaripa4, Zachary Wallace5, Elizabeth Regan6, Gary Hunninghake1, Edwin Silverman1, Samuel Ash1, Raul San Jose Estepar1, George Washko1 and Jeffrey Sparks7, 1Brigham and Women's Hospital, Boston, MA, 2Division of Rheumatology, Inflammation, and Immunity Brigham & Women's Hospital, Boston, MA, 3University of Colorado Denver, Denver, CO, 4Brigham and Women's Hospital, Boston, MA, 5Massachusetts General Hospital, Newton, MA, 6National Jewish Health, Denver, CO, 7Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Rheumatoid arthritis (RA) has known extra-articular manifestations that can result in restrictive and obstructive patterns on pulmonary function measures, especially in smokers. However, investigations…
  • Abstract Number: 2126 • ACR Convergence 2023

    Performance of the Rheumatoid Arthritis Impact of Disease (RAID) Score in Relation to Flares in Disease Activity

    Karen Holten, Nina Paulshus Sundlisæter, Joseph Sexton, Lena Bugge Nordberg, Till Uhlig, Tore Kvien, Espen Haavardsholm, Siri Lillegraven and Anna-Birgitte Aga, Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway

    Background/Purpose: The Rheumatoid Arthritis Impact of Disease (RAID) is a patient-reported outcome measure (PROM) originating from a EULAR initiative. It might support patient-centred care and…
  • Abstract Number: 2142 • ACR Convergence 2023

    Adherence Patterns in Rheumatoid Arthritis Patients Receiving a Janus Kinase (JAK) Inhibitor or a Tumor Necrosis Factor α Inhibitor (TNFi) After the Addition of a Black Box Warning to JAK Inhibitors

    W. Cliff Rutter, Kunal Patel, Samantha Delgado, Guy Cozzi, Elisea Avalos-Reyes, Will Cavers, Chen Liu, Rashmi Grover, Lucia Feczko and Kjel Johnson, CVS Health, Woonsocket, RI

    Background/Purpose: In 2021, the FDA concluded that there is an increased risk of serious heart-related events with the Janus Kinase (JAK) inhibitor tofacitinib, which is…
  • Abstract Number: 2158 • ACR Convergence 2023

    Continued Nintedanib Treatment in Patients with Progressive Pulmonary Fibrosis Related to Autoimmune Disease: Data from INBUILD-ON

    Eric Matteson1, Danielle Antin-Ozerkis2, Francesco Bonella3, Nazia Chaudhuri4, Vincent Cottin5, Heiko Mueller6, Steven Sambevski7 and Wim A Wuyts8, 1Mayo Clinic College of Medicine and Science, Rochester, MN, USA, Rochester, MN, 2Section of Pulmonary, Critical Care and Sleep Medicine, Yale University School of Medicine, New Haven, CT, 3Center for Interstitial and Rare Lung Diseases, Pneumology Department, Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany, 4North West Interstitial Lung Disease Unit, Manchester University Foundation Trust, Wythenshawe, Manchester, United Kingdom, 5Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France, 6Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, Biberach, Germany, 7Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, 8Unit for Interstitial Lung Diseases, Department of Pulmonary Medicine, University Hospitals Leuven, Leuven, Belgium

    Background/Purpose: In the INBUILD trial in patients with progressive pulmonary fibrosis, nintedanib reduced the rate of decline in forced vital capacity (FVC) compared with placebo,…
  • Abstract Number: 2175 • ACR Convergence 2023

    Real-World Drug Persistence of GP2015, an Etanercept Biosimilar, in Patients with Rheumatoid Arthritis: Results from the Multi-Country COMPACT Study

    Marc Schmalzing1, Charlotte Both2, Ines Brueckmann2, Javier de Toro Santos3, Tom Sheeran4, Herbert Kellner5 and Ayman Askari6, 1University Hospital, Rheumatology/Clinical Immunology, Department of Internal Medicine II, Würzburg, Germany, 2Sandoz Hexal AG, Rheumatology, Holzkirchen, Germany, 3University Hospital Coruña, Rheumatology, A Coruña, Spain, 4University of Wolverhampton, New Cross Hospital, Wolverhampton, United Kingdom, 5Hospital Neuwittelsbach, Center for Rheumatology and Gastroenterology, Munich, Germany, 6Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust, Rheumatology, Shropshire, United Kingdom

    Background/Purpose: COMPACT is a multi-country, non-interventional study that evaluated the drug persistence, effectiveness, safety and patient-reported outcomes in patients with rheumatoid arthritis (RA), axial spondyloarthritis…
  • Abstract Number: 2479 • ACR Convergence 2023

    Tolerability and Effectiveness of Antifibrotics in Rheumatoid Arthritis-associated Interstitial Lung Disease

    Pierre-Antoine Juge1, Keigo Hayashi2, Gregory McDermott2, Kathleen Vanni2, Emily Kowalski2, Grace Qian2, Katarina Bade3, Alene Saavedra2, Philippe Dieudé4, Paul Dellaripa3, Tracy J. Doyle2 and Jeffrey Sparks5, 1Division of Rheumatology, Inflammation, and Immunity Brigham & Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Boston, MA, 3Brigham and Women's Hospital, Boston, MA, 4Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, INSERM UMR1152, University de Paris Cité, Department of Rheumatology, Paris, France, 5Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Nintedanib and pirfenidone are antifibrotic drugs indicated for the treatment of idiopathic pulmonary fibrosis (IPF) and other forms of progressive pulmonary fibrosis. Antifibrotics have…
  • Abstract Number: 2567 • ACR Convergence 2023

    An Extended Interval Between mRNA COVID-19 Booster Vaccinations Is Associated with an Increased Humoral Immune Response in Patients with Inflammatory Rheumatic Diseases

    Catherine Raptis1, Christoph Berger2, Christos Polysopoulos1, Adrian Ciurea3, Diego Andrey4, Tanja Maletic1, Myriam Riek1, Almut Scherer1, Isabell von Loga1, Judith Safford1, Kim Lauper5, Burkhard Moeller6, Nicolas Vuilleumier4, Axel Finckh7 and Andrea Rubbert-Roth8, 1SCQM Foundation, Zurich, Switzerland, 2University Hospital Basel, Basel, Switzerland, 3University Hospital Zurich, Zürich, Switzerland, 4Geneva University Hospitals, Geneva, Switzerland, 5Geneva University Hospitals, Genève, Switzerland, 6Inselspital - University Hospital Bern, Bern, Switzerland, 7HUG, Geneva, Switzerland, 8Cantonal Hospital St. Gallen, St. Gallen, Switzerland

    Background/Purpose: There is evidence that extending the interval between COVID-19 vaccination doses is associated with increased immunogenicity and neutralizing activity in healthy individuals (1, 2).…
  • « Previous Page
  • 1
  • …
  • 47
  • 48
  • 49
  • 50
  • 51
  • …
  • 188
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology